177 related articles for article (PubMed ID: 16159455)
41. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
42. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
Trémollieres F; Pouilles JM; Ribot C
Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
[TBL] [Abstract][Full Text] [Related]
43. [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].
Korsić M; Giljević Z; Kastelan D
Lijec Vjesn; 2006; 128(5-6):180-2. PubMed ID: 16910420
[TBL] [Abstract][Full Text] [Related]
44. [Therapeutic agents for disorders of bone and calcium metabolism. Osteoporotic fracture prevention by strontium ranelate].
Nakamura T
Clin Calcium; 2007 Jan; 17(1):80-7. PubMed ID: 17211097
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
[TBL] [Abstract][Full Text] [Related]
46. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis.
Burlet N; Reginster JY
Clin Orthop Relat Res; 2006 Feb; 443():55-60. PubMed ID: 16462426
[TBL] [Abstract][Full Text] [Related]
47. Prospective assessment of thoracic kyphosis in postmenopausal women with osteoporosis.
Roux C; Fechtenbaum J; Kolta S; Said-Nahal R; Briot K; Benhamou CL
J Bone Miner Res; 2010 Feb; 25(2):362-8. PubMed ID: 19594302
[TBL] [Abstract][Full Text] [Related]
48. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
Delmas PD
Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
[TBL] [Abstract][Full Text] [Related]
49. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
[TBL] [Abstract][Full Text] [Related]
50. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
Reginster JY; Deroisy R; Dougados M; Jupsin I; Colette J; Roux C
Osteoporos Int; 2002 Dec; 13(12):925-31. PubMed ID: 12459934
[TBL] [Abstract][Full Text] [Related]
51. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
Deeks ED; Dhillon S
Drugs; 2010 Apr; 70(6):733-59. PubMed ID: 20394457
[TBL] [Abstract][Full Text] [Related]
52. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
Marie PJ
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
[TBL] [Abstract][Full Text] [Related]
53. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
Boivin G; Meunier PJ
Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
[TBL] [Abstract][Full Text] [Related]
54. Strontium ranelate--does it affect the management of postmenopausal osteoporosis?
Winzenberg T; Powell S; Jones G
Aust Fam Physician; 2007 Aug; 36(8):631-2. PubMed ID: 17676187
[TBL] [Abstract][Full Text] [Related]
55. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.
Bruyère O; Roux C; Badurski J; Isaia G; de Vernejoul MC; Cannata J; Ortolani S; Slosman D; Detilleux J; Reginster JY
Curr Med Res Opin; 2007 Dec; 23(12):3041-5. PubMed ID: 17967221
[TBL] [Abstract][Full Text] [Related]
56. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
Marie PJ
Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
[TBL] [Abstract][Full Text] [Related]
57. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate.
Manette C; Collette J; Sarlet N; Tancredi A; Zegels B; Reginster JY
Curr Med Chem; 2006; 13(13):1585-90. PubMed ID: 16787205
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
Liu JM; Wai-Chee Kung A; Pheng CS; Zhu HM; Zhang ZL; Wu YY; Xu L; Meng XW; Huang ML; Chung LP; Hussain NH; Sufian SS; Chen JL
Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
[TBL] [Abstract][Full Text] [Related]
60. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.
Roux C; Fechtenbaum J; Kolta S; Isaia G; Andia JB; Devogelaer JP
Ann Rheum Dis; 2008 Dec; 67(12):1736-8. PubMed ID: 18713788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
